Liu, Xiaomei I.
Momper, Jeremiah D.
Rakhmanina, Natella Y.
Green, Dionna J.
Burckart, Gilbert J.
Cressey, Tim R.
Mirochnick, Mark
Best, Brookie M.
van den Anker, John N.
Dallmann, André
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (UM1AI068632, UM1AI106716)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (UM1AI068616)
National Institute of Child Health and Human Development (5T32HD087969-03, 5T32087969-02)
Article History
Accepted: 12 December 2020
First Online: 2 February 2021
Declarations
:
: Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health, all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC), and UM1AI106716 (IMPAACT LC), and by NICHD contract number HHSN275201800001I. The NIH awards numbers 5T32HD087969-03 and 5T32HD087969-02 also support this project.
: Xiaomei I. Liu, Jeremiah D. Momper, Natella Y. Rakhmanina, Dionna J. Green, Gilbert J. Burckart, Tim R. Cressey, Mark Mirochnick, Brookie M. Best, John N. van den Anker, and André Dallmann have no conflicts of interest with respect to the research, authorship, and/or publication of this article. André Dallmann is an employee of Bayer AG, a company that is part of the Open Systems Pharmacology member team and involved in the Open Systems Pharmacology software development used in this study. The results from this study will be presented in part at the American College of Clinical Pharmacology Annual Meeting, September 2020.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.